Stock · DXCM · Healthcare
United States · Large Cap · listed since 2005 · Revenue 12 mo. $5B
Price as of 11/06/2026
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Original text from the data provider
Summary
56.3 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €966.7M (2025), it supports €10.7B. The remaining €15.1B of the market value assume it grows 12.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.2%
no growth afterwards
Price to operating cash flow 17.8×, below its usual range.
Middle half of 20 quarters: 31.2× to 71.9×, median 53.1×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 30.46% | 11.52% | Rank 85 |
| Return on capital (Greenblatt) | 25.84% | 32.55% | Rank 37 |
| EBIT margin | 19.56% | 18.31% | Rank 57 |
| FCF margin | 23.11% | 14.12% | Rank 79 |
| Gross margin | 60.10% | 60.99% | Rank 48 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 15.60% | 8.04% | Rank 82 |
| Earnings growth, 3 years per year | 37.22% | 5.44% | Rank 85 |
| Earnings growth, 5 years per year | 10.26% | 7.00% | Rank 59 |
| Sustainable growth (ROE × retained earnings) | 7.80% | 3.66% | Rank 88 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.60% | 2.90% | Rank 41 |
| FCF yield | 3.75% | 3.63% | Rank 51 |
| EV/saleslower is better | 6.04 | 4.03 | Rank 34 |
| EV/EBITlower is better | 30.87 | 21.73 | Rank 26 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 27.26% | 8.66% | Rank 77 |
| Share price, 6 months | 31.50% | 24.27% | Rank 67 |
| Share price, 3 months | −1.17% | 15.42% | Rank 12 |
| Distance from 52-week high | −14.00% | −7.35% | Rank 32 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −17.78% | 0.30% | Rank 98 |
| Change in share countlower is better | −1.74% | 0.00% | Rank 75 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | 4.55% | 0.05% | Rank 82 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 43.31% | 48.40% | Rank 39 |
| Net debt/EBITDAlower is better | −0.45 | 1.11 | Rank 75 |
| Debt to equitylower is better | 0.51 | 0.48 | Rank 49 |
| Volatility, 1 yearlower is better | 40.38% | 31.42% | Rank 23 |
Ten years in figures
| Year | Revenue | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | $573.3M | −11.2% | $500.0K | 334M | −$88.5M |
| 2017 | $718.5M | −5.9% | $26.0M | 345M | −$113.9M |
| 2018 | $1.0B | −18.1% | $56.1M | 353M | −$126.7M |
| 2019 | $1.5B | 9.6% | $134.5M | 369M | $713.9M |
| 2020 | $1.9B | 15.5% | $276.6M | 390M | $1.0B |
| 2021 | $2.4B | 10.9% | $53.3M | 429M | $1.1B |
| 2022 | $2.9B | 13.4% | $304.7M | 428M | $1.5B |
| 2023 | $3.6B | 16.5% | $511.9M | 426M | $2.0B |
| 2024 | $4.0B | 14.9% | $630.7M | 413M | $2.0B |
| 2025 | $4.7B | 19.6% | $1.1B | 406M | $472.0M |
6 of 7 StockScorer Score rules met · How the score is built
DexCom Inc mainly meets criteria in the Growth category. Result from 18 strategies checked.
DexCom Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
6 of 7 rules met
9 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for DexCom Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 38.5 | 30.0 |
| P/B ratio | 11.7 | 4.8 |
| Return on equity (ROE) | 30.5% | 11.5% |
| Equity ratio | 43.3% | 48.4% |
| Debt-to-equity (D/E) | 0.51 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| DXCM | DexCom Incthis page | |
| STE | STERIS plc | Low4.5 |
| GEHC | GE HealthCare Technologies Inc. | Low4.5 |
| ZBH | Zimmer Biomet Holdings Inc | Low4.5 |
| GKOS | Glaukos Corp | locked |
| PEN | Penumbra Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.